Sarepta Landing Page

JWCA has advised Sarepta on capital market transactions with over $2.0 BILLION in transaction Value

August 2025: JWCA advises Sarepta Therapeutics on the exchange of $700 million of its existing convertible into a new $602 million convertible plus cash and shares

March 2023: JWCA advises Sarepta on the equitization of $313.5mm of its convertible notes

September 2022: JWCA advises Sarepta on its $1.15 billion convertible and capped call transaction